X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (45) 45
index medicus (45) 45
hematology (33) 33
male (32) 32
middle aged (32) 32
female (30) 30
adult (23) 23
aged (23) 23
oncology (15) 15
abridged index medicus (12) 12
life sciences (12) 12
treatment outcome (12) 12
aged, 80 and over (11) 11
retrospective studies (11) 11
cancer (10) 10
prognosis (10) 10
leukemia (9) 9
transplantation (9) 9
chronic myeloid leukemia (8) 8
disease-free survival (8) 8
hematology, oncology and palliative medicine (8) 8
transplantation, homologous (8) 8
hematopoietic stem cell transplantation - adverse effects (7) 7
human health and pathology (7) 7
recommendations (7) 7
survival rate (7) 7
time factors (7) 7
young adult (7) 7
adolescent (6) 6
analysis (6) 6
france (6) 6
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (6) 6
nilotinib (6) 6
patients (6) 6
remission induction (6) 6
survival analysis (6) 6
cells (5) 5
chronic myelogenous leukemia (5) 5
diagnosis (5) 5
fusion proteins, bcr-abl - genetics (5) 5
imatinib (5) 5
incidence (5) 5
leukemia, myeloid, chronic-phase - drug therapy (5) 5
management (5) 5
multiple myeloma (5) 5
pyrimidines - therapeutic use (5) 5
risk (5) 5
risk factors (5) 5
stem cells (5) 5
survival (5) 5
therapy (5) 5
allogeneic stem cell transplantation (4) 4
antineoplastic agents - therapeutic use (4) 4
follow-up (4) 4
follow-up studies (4) 4
hematologic neoplasms - therapy (4) 4
hematopoietic stem cell transplantation (4) 4
molecular response (4) 4
multiple myeloma - pathology (4) 4
patient outcomes (4) 4
protein kinase inhibitors - therapeutic use (4) 4
research (4) 4
amyloidosis (3) 3
animals (3) 3
bcr-abl1 (3) 3
benzamides (3) 3
bone marrow transplantation (3) 3
bone-marrow-transplantation (3) 3
case-control studies (3) 3
chemotherapy (3) 3
child, preschool (3) 3
chronic disease (3) 3
chronic gvhd (3) 3
clinical trials (3) 3
cml (3) 3
confidence intervals (3) 3
drug therapy (3) 3
epidemiology (3) 3
erythrocyte transfusion (3) 3
graft vs host disease - drug therapy (3) 3
graft vs host disease - mortality (3) 3
health aspects (3) 3
hematologic neoplasms - complications (3) 3
hematologic neoplasms - mortality (3) 3
imatinib mesylate (3) 3
immunology (3) 3
infection (3) 3
leukemia, myelogenous, chronic, bcr-abl positive - genetics (3) 3
lymphoma (3) 3
medical research (3) 3
medicine, general & internal (3) 3
mortality (3) 3
multiple myeloma - genetics (3) 3
multiple myeloma - mortality (3) 3
multiple-myeloma (3) 3
myeloid leukemia (3) 3
original (3) 3
predictive value of tests (3) 3
recombinant proteins (3) 3
recurrence (3) 3
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JAMA, ISSN 0098-7484, 08/2017, Volume 318, Issue 6, pp. 557 - 566
IMPORTANCE: Bronchiolitis obliterans syndrome has been associated with increased morbidity and mortality after allogeneic hematopoietic stem cell transplant... 
MEDICINE, GENERAL & INTERNAL | LUNG TRANSPLANTATION | BRONCHIOLITIS OBLITERANS SYNDROME | THERAPY | EFFICACY | REJECTION | PULMONARY COMPLICATIONS | RISK | MICROBIOTA | LEUKEMIA | VERSUS-HOST-DISEASE | Hematologic Neoplasms - therapy | Recurrence | Double-Blind Method | Bronchiolitis Obliterans - etiology | Hematologic Neoplasms - mortality | Humans | Middle Aged | Male | Transplantation, Homologous | Bronchiolitis Obliterans - prevention & control | Anti-Bacterial Agents - therapeutic use | Azithromycin - adverse effects | Disease-Free Survival | Azithromycin - therapeutic use | Treatment Failure | Hematopoietic Stem Cell Transplantation - adverse effects | Intention to Treat Analysis | Adult | Female | Anti-Bacterial Agents - adverse effects | Respiratory Function Tests | Transplantation Conditioning | Complications and side effects | Usage | Patient outcomes | Analysis | Lung diseases | Azithromycin | Stem cells | Dosage and administration | Transplantation | Pulmonary ventilation | Drug therapy | Risk factors | Respiratory function | Transplants & implants | Syngeneic grafts | Lung | Bronchopneumonia | Lung transplantation | Clinical trials | Stem cell transplantation | Malignancy | Incidence | Randomization | Motivation | Safety engineering | Bronchiolitis obliterans | Cell survival | Hematology | Mortality | Patients | Survival | Morbidity | Hemopoiesis | Air flow | Respiratory diseases | Pulmonary functions | Index Medicus | Abridged Index Medicus | Original Investigation | Research
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2010, Volume 363, Issue 26, pp. 2511 - 2521
In this study, adding pegylated interferon alfa-2a to imatinib therapy for chronic myeloid leukemia resulted in a greater reduction in the number of cells... 
CHRONIC MYELOGENOUS LEUKEMIA | MEDICINE, GENERAL & INTERNAL | CHRONIC GRANULOCYTIC-LEUKEMIA | INTERFERON | POSITIVE CELLS | CHRONIC-PHASE | ABL TYROSINE KINASE | HEMATOPOIETIC STEM-CELLS | FOLLOW-UP | PATIENTS RECEIVING IMATINIB | CYTARABINE | Piperazines - administration & dosage | Humans | Leukemia, Myeloid, Chronic-Phase - pathology | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Polyethylene Glycols - adverse effects | Male | Proto-Oncogene Proteins c-abl - analysis | Cytarabine - adverse effects | Recombinant Proteins | RNA, Neoplasm - analysis | Adult | Female | Transcription, Genetic | Neutropenia - chemically induced | Proto-Oncogene Proteins c-abl - genetics | Pyrimidines - administration & dosage | Leukemia, Myeloid, Chronic-Phase - drug therapy | Anemia - chemically induced | Treatment Outcome | Thrombocytopenia - chemically induced | Imatinib Mesylate | Piperazines - adverse effects | Remission Induction | Cytarabine - administration & dosage | Polyethylene Glycols - administration & dosage | Interferon-alpha - administration & dosage | Leukemia, Myeloid, Chronic-Phase - mortality | Fusion Proteins, bcr-abl - genetics | Fusion Proteins, bcr-abl - analysis | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrimidines - adverse effects | Survival Analysis | Stem Cells - drug effects | Interferon-alpha - adverse effects | Benzamides | Drug therapy | Chronic myeloid leukemia | Medical research | Kinases | Leukemia | Manuscripts | Index Medicus | Abridged Index Medicus
Journal Article
Blood, ISSN 0006-4971, 01/2008, Volume 111, Issue 2, pp. 574 - 582
Journal Article
Cancer, ISSN 0008-543X, 05/2017, Volume 123, Issue 10, pp. 1791 - 1799
Journal Article
Blood, ISSN 0006-4971, 07/2007, Volume 110, Issue 1, pp. 296 - 304
Multiple myeloma (MM) cells inhibit certain T-cell functions. We examined the expression of B7-H1 (PD-L1), a B7-related protein that inhibits T-cell responses,... 
CARCINOMA PATIENTS | INTERFERON-GAMMA | DENDRITIC CELLS | TOLL-LIKE RECEPTORS | B7 FAMILY | TUMOR-CELLS | BLOCKADE | HEMATOLOGY | POTENTIAL MECHANISM | CD8(+) T-CELLS | CTL-MEDIATED LYSIS
Journal Article
Cancer, ISSN 0008-543X, 07/2018, Volume 124, Issue 14, pp. 2956 - 2963
Clinical trials have demonstrated that patients with chronic‐phase chronic myeloid leukemia with deep and durable molecular responses can attempt to stop using... 
tyrosine kinase inhibitors | chronic myeloid leukemia | clinical practice | treatment discontinuation | recommendations | TREATMENT-FREE REMISSION | MANAGEMENT | IMATINIB CESSATION | DASATINIB | NILOTINIB | RELAPSE | IMPACT | ONCOLOGY | DISEASE | DEEP MOLECULAR RESPONSE | CML PATIENTS | Prognosis | Age Factors | Fusion Proteins, bcr-abl - isolation & purification | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Patient Selection | Young Adult | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Fusion Proteins, bcr-abl - blood | Adult | Remission Induction - methods | France | Neoplasm Recurrence, Local - blood | Watchful Waiting - standards | Patient Education as Topic | Medical Oncology - methods | Neoplasm Recurrence, Local - prevention & control | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - blood | Hematology - standards | Treatment Outcome | Neoplasm Recurrence, Local - diagnosis | Consensus | Hematology - methods | Protein Kinase Inhibitors - therapeutic use | Fusion Proteins, bcr-abl - antagonists & inhibitors | Medical Oncology - standards | Fusion Proteins, bcr-abl - metabolism | Tyrosine | Medical personnel | Myeloid leukemia | Physicians | Leukemia | Medical services | Chronic myeloid leukemia | Patients | Reintroduction | Biologists | Molecular chains | Training | Remission | Clinical medicine | Protein-tyrosine kinase | Monitoring | Cancer | Index Medicus | Abridged Index Medicus | Life Sciences | Hematology | Human health and pathology
Journal Article
Journal Article
Blood, ISSN 0006-4971, 02/2017, Volume 129, Issue 7, pp. 846 - 854
Journal Article
Journal Article